Gene Editing in Hematologic Stem Cell Therapies
Welcome to our article on gene editing techniques in hematologic stem cell therapy. Gene therapy holds immense promise in the field of medicine, offering the potential to treat various blood disorders by modifying the cell genome. In the context of hematologic stem cell therapy, gene editing techniques using programmable nucleases have shown remarkable advancements, bringing […]
Stem Cells: Hope for Neuromuscular Diseases
Neuromuscular diseases, such as ALS and muscular dystrophy, can have a devastating impact on the lives of those affected. These conditions, which involve muscle disorders and neurological damage, often result in nerve degeneration and impaired muscle function. However, advancements in regenerative medicine are offering new hope for patients. Stem cell therapy, a form of cell […]
RoslinCT and the Revolutionary CRISPR-Based Gene Therapy CASGEVY™
RoslinCT, a renowned cell and gene therapy Contract Development and Manufacturing Organisation (CDMO), has achieved a groundbreaking milestone in the field of medical science. Building on its legacy since the cloning of Dolly the Sheep at the Roslin Institute in 1997, RoslinCT has now been entrusted with the manufacturing of the first-ever U.S. Food and […]
RoslinCT Unveils CRISPR: A Medical Revolution Begins
RoslinCT, a renowned cell and gene therapy Contract Development and Manufacturing Organisation (CDMO), has announced a significant advancement in the field of medical science. They will be manufacturing the world’s first CRISPR-based therapy, exa-cel, for Vertex Pharmaceuticals Inc. This development follows an extensive collaboration between the two entities. Key Highlights: About RoslinCT: RoslinCT has a […]
Be The Match BioTherapies and Cryoport Join Forces to Propel Cell and Gene Therapy Advancements
In a groundbreaking move, Be The Match BioTherapies®, a pioneering organization that offers solutions for companies venturing into the development and commercialization of cell and gene therapies, has announced a strategic partnership with Cryoport, a global leader in providing innovative products and services to the rapidly evolving cell & gene therapy sector. A Partnership for […]
Orchard Therapeutics Moves Closer to a Breakthrough Treatment for MLD
Orchard Therapeutics, a global leader in gene therapy, has recently made significant strides in the development of a treatment for metachromatic leukodystrophy (MLD). Here’s a detailed summary of the press release: Key Developments: Insights from Orchard Therapeutics: Bobby Gaspar, M.D., Ph.D., co-founder and CEO of Orchard Therapeutics, expressed the company’s commitment to addressing the urgent […]
Excision BioTherapeutics’ Groundbreaking Gene Therapy for HIV: A Closer Look
Excision BioTherapeutics, a clinical-stage biotechnology company, has recently made headlines with its announcement regarding the publication of pre-clinical data supporting its innovative CRISPR-based gene therapy candidate, EBT-101. This therapy is designed to functionally cure HIV-1. Here’s a detailed summary of the press release: Key Findings: CEO’s Statement: Daniel Dornbusch, the Chief Executive Officer of Excision, […]
RoslinCT and Lykan Bioscience: The Dynamic Duo Redefining the Future of Cell and Gene Therapy
RoslinCT and Lykan Bioscience, two leading Contract Development and Manufacturing Organizations (CDMOs) in the Cell and Gene Therapy industry, have announced their integration to form a unified business that will operate under the RoslinCT brand. This integration, facilitated by GHO Capital, a global investment firm, aims to establish a dominant player in the Advanced Cell […]
Cell BioEngines Enters into an Exclusive Worldwide Agreement to Develop and Commercialize Potent Immune Cell States to Cure Cancer
BOSTON and NEW YORK, Jan. 25, 2023 (GLOBE NEWSWIRE) — Cell BioEngines Inc. (the “Company”), a cell and gene therapy company focused on developing an allogenic cell-based product for solid tumors, today announced that it has entered into an exclusive license agreement with Icahn School of Medicine at Mount Sinai (“Icahn Mount Sinai”), in New […]
Cell and Gene Therapy Companies Leverage GenScript’s cGMP sgRNA Capability to Accelerate Speed to Market
PISCATAWAY, N.J., Dec. 15, 2022 /PRNewswire/ — GenScript USA Inc., the world’s leading life-science service provider, recently expanded its global current Good Manufacturing Practices (cGMP) single-guide RNA (sgRNA) manufacturing capabilities to meet the growing demand for cell and gene therapies. GenScript’s 400,000 square-foot cGMP facility enables next-generation gene and cell therapy R&D programs to advance IND filings and clinical trials. “We are […]